Rifapentine vs Rifabutin — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Rifamycin Antimycobacterial

Rifapentine

Brand: Priftin

First FDA approval: 2017-02-08

Rifamycin Antimycobacterial

Rifabutin

First FDA approval: 2014-04-07

Lowest NADACAcquisition cost floor across all NDCs

$4.85Per unit

$9.18Per unit

Average NADACAcross all dosage forms and strengths

$4.85Up to $4.85

$9.18Up to $9.18

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

11 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$818510Full year

$10.4MFull year

Part D claims (CY24)Total fills, all strengths

4K3K beneficiaries

25K12K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$184Per claim, all NDCs

$413Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

Active shortageSee drug profile

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes1 manufacturers